Advertisement

Topics

Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 02/06/1998, Revision: 45, Status: Authorised

07:07 EDT 12 Jul 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 02/06/1998, Revision: 45, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 02/06/1998, Revision: 45, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): MabThera, rituximab, Lymphoma, Non-Hodgkin,Arthritis, Rheumatoid,Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 02/06/1998, Revision: 45, Status: Authorised"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...